Compass Therapeutics to Participate in Upcoming May Investor Events
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compass Therapeutics (Nasdaq:CMPX) will participate in two May 2026 investor conferences focused on biotechnology and oncology.
The company presents at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19 at 1:30 PM ET, and at the 2026 Stifel Virtual Targeted Oncology Forum on May 20 at 11:30 AM ET. Both presentations are accessible via webcast, with replays available on the company’s Events page. Management will be available for one-on-one investor meetings arranged through conference representatives.
Details
News Market Reaction – CMPX
On May 12, the day this news came out, CMPX closed 2.19% above the previous close.
Data tracked by StockTitan Argus for the May 12 session.
Key Figures
- H.C. Wainwright conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- H.C. Wainwright presentation time
- 1:30 PM ET
- Scheduled investor presentation time
- Stifel forum date
- May 20, 2026
- 2026 Stifel Virtual Targeted Oncology Forum
- Stifel forum time
- 11:30 AM ET
- Scheduled investor presentation time
- Conference sequence
- 4th Annual
- H.C. Wainwright BioConnect Investor Conference edition
Historical Context
-
Q1 2026 results, positive tovecimig data, strong cash runway into 2028.
-
COMPANION-002 Phase 2/3 data showing PFS and ORR benefit in biliary cancer.
-
Announcement of upcoming webcast to review COMPANION-002 topline endpoints.
-
2025 results, tovecimig ORR success, IND clearance for CTX-10726, runway to 2028.
-
Pipeline progress, tovecimig PFS/OS plans, CTX-8371 expansions, $209M cash estimate.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 19, 2026
Time: 1:30 PM ET
Webcast Link: https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f
2026 Stifel Virtual Targeted Oncology Forum
Date: Wednesday, May 20, 2026
Time: 11:30 AM ET
Webcast Link: https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6
Virtual/Replay availability: Presentations will be archived on Compass’ Events page.
Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
About Compass Therapeutics
Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.